Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 5/20 | 0.88 |
| ▸ | POLB | P06746 | 3/20 | 0.88 |
| ▸ | GAA | P10253 | 3/20 | 0.88 |
| ▸ | XDH | P47989 | 2/20 | 0.88 |
| ▸ | APEX1 | P27695 | 2/20 | 0.88 |
| ▸ | RECQL | P46063 | 2/20 | 0.88 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | HES1 | Q14469 | 2/20 | 0.78 |
| ▸ | FANCF | Q9NPI8 | 2/20 | 0.78 |
| ▸ | KDM1A | O60341 | 1/20 | 0.78 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.78 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.78 |
| ▸ | CFTR | P13569 | 1/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.78 |
| ▸ | MAOA | P21397 | 1/20 | 0.78 |
| ▸ | ACHE | P22303 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mauritianin SCHEMBL30003610 | 1.00 | P4HB (0.88) | P4HBPOLBGAAXDHAPEX1 | |
| Mauritianin SCHEMBL572331 | 1.00 | P4HB (0.88) | P4HBPOLBGAAXDHAPEX1 | |
| Mauritianin SCHEMBL572330 | 1.00 | P4HB (0.88) | P4HBPOLBGAAXDHAPEX1 | |
| Mauritianin SCHEMBL18167030 | 1.00 | P4HB (0.88) | P4HBPOLBGAAXDHAPEX1 | |
| SCHEMBL29436868 | 0.98 | P4HB (0.84) | P4HBPOLBGAAXDHAPEX1 | |
| Camelliaside A SCHEMBL29882538 | 0.97 | P4HB (0.83) | P4HBPOLBGAAXDHAPEX1 | |
| Camelliaside A SCHEMBL14813695 | 0.97 | P4HB (0.83) | P4HBPOLBGAAXDHAPEX1 | |
| Camelliaside A SCHEMBL13328501 | 0.97 | P4HB (0.83) | P4HBPOLBGAAXDHAPEX1 | |
| Camelliaside A SCHEMBL30637486 | 0.97 | P4HB (0.83) | P4HBPOLBGAAXDHAPEX1 | |
| SCHEMBL22678451 | 0.97 | P4HB (0.88) | P4HBPOLBGAAXDHAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9381222-B2 | Compositions for preventing and treating obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes or metabolic syndrome containing extracts of glycine max leaves or fractions isolated from the same as an active ingredient | Korea Reasearch Institute of Bioscience and Biotechnology (KR) | 2016-07-05 | — | — | US | claimed |
| US-9381222-B2 | Compositions for preventing and treating obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes or metabolic syndrome containing extracts of glycine max leaves or fractions isolated from the same as an active ingredient | Korea Reasearch Institute of Bioscience and Biotechnology (KR) | 2016-07-05 | — | — | US | disclosed |
| US-20100291248-A1 | Compositions for Preventing and Treating Obesity, Hyperlipidemia, Atherosclerosis, Fatty Liver, Diabetes or Metabolic Syndrome Containing Extracts of Glycine Max Leaves or Fractions Isolated from the Same as an Active Ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291248-A1 | Compositions for Preventing and Treating Obesity, Hyperlipidemia, Atherosclerosis, Fatty Liver, Diabetes or Metabolic Syndrome Containing Extracts of Glycine Max Leaves or Fractions Isolated from the Same as an Active Ingredient | AGXT, LIPC, GYS2 | P4HB 4533/4885POLB 3360/4885GAA 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.